- Home
- AACG vs COEP Comparison
AACG vs COEP Comparison
Compare AACG & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACG
- COEP
- Stock Information
- Founded
- AACG 1999
- COEP 2017
- Country
- AACG China
- COEP United States
- Employees
- AACG N/A
- COEP N/A
- Industry
- AACG Other Consumer Services
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AACG Real Estate
- COEP Health Care
- Exchange
- AACG Nasdaq
- COEP Nasdaq
- Market Cap
- AACG 27.1M
- COEP 30.5M
- IPO Year
- AACG N/A
- COEP N/A
- Fundamental
- Price
- AACG $0.87
- COEP $9.70
- Analyst Decision
- AACG
- COEP
- Analyst Count
- AACG 0
- COEP 0
- Target Price
- AACG N/A
- COEP N/A
- AVG Volume (30 Days)
- AACG 40.9K
- COEP 42.3K
- Earning Date
- AACG 05-13-2025
- COEP 05-09-2025
- Dividend Yield
- AACG N/A
- COEP N/A
- EPS Growth
- AACG N/A
- COEP N/A
- EPS
- AACG N/A
- COEP N/A
- Revenue
- AACG $36,725,098.00
- COEP N/A
- Revenue This Year
- AACG N/A
- COEP N/A
- Revenue Next Year
- AACG N/A
- COEP N/A
- P/E Ratio
- AACG N/A
- COEP N/A
- Revenue Growth
- AACG 20.95
- COEP N/A
- 52 Week Low
- AACG $0.50
- COEP $2.31
- 52 Week High
- AACG $1.16
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- AACG 42.35
- COEP 45.50
- Support Level
- AACG $0.93
- COEP $9.01
- Resistance Level
- AACG $1.03
- COEP $9.75
- Average True Range (ATR)
- AACG 0.06
- COEP 0.83
- MACD
- AACG -0.01
- COEP -0.03
- Stochastic Oscillator
- AACG 23.81
- COEP 46.07
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments are Overseas art study services, Other educational services and K-12 education assessment and other services. Majority of its revenue comes from Overseas art study services.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.